Abstract: The present invention provides a novel culture medium and method for culturing stem cells, preferably muscle-derived mesenchymal stem cells. The culture medium comprises clotted blood plasma at 5-70% in base medium. The cultured cells may be released without use of trypsin by resolubilizing the clotted blood plasma with the assistance of proteolytic enzymes or anticoagulation agents.

Abstract: The present invention relates to a method for preparing differentiated mammalian cells comprising collecting muscle microbiopsy, placing the sample in a cell culture medium, collecting and growing the cells and differentiating them in suitable differentiation medium.

Abstract: The present invention relates to a method for assessing the effects of a compound or composition on a mammal, comprising obtaining mammalian pluripotent muscle-derived mesenchymal stem cells or a population thereof, exposing the said stem cells, stem cell population to the relevant compound or composition, and assessing the effects on the said cells. The invention method is a reliable assessment method applicable to drug development, toxicity testing and optimized personalized medicine.

Abstract: The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of MSCs that can differentiate into different cell lineages.

Abstract: The invention relates to a multi-site production system for production of a product under regulated conditions comprising at least two production sites (12) linked to a central monitoring unit (10), each production site (12) comprising at least one production unit (16) for production under regulated conditions and a computerized control unit (14) designed to receive, possibly record, and transfer required product and/or process parameters to the central monitoring unit (10) designed to check for validation purposes the production process and/or product quality. The invention further relates to a method for multi-site production under regulated conditions making use of above system.

Abstract: The invention provides an in vitro method or assay for the diagnosis of osteochondrosis or prediction of the likelihood of its onset in a terrestrian mammal, comprising measuring the expression level of a marker in a sample obtained from said terrestrian mammal and comparing said expression level to the expression level of said marker measured in a sample obtained from one or more terrestrian mammals of the same species not affected by osteochondrosis, wherein the marker is ApoB-3G, and wherein an increase in the expression level of ApoB-3G is indicative of osteochondrosis. The invention also provides a diagnostic kit for use in said method, which comprises at least one agent, which binds specifically to the product of the gene of the respective marker and which can be used to determine the expression level of said marker, wherein the marker is ApoB-3G.

Abstract: The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of MSCs that can differentiate into different cell lineages.

Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.

Abstract: The invention provides an in vitro method or assay for the diagnosis of osteochondrosis or prediction of the likelihood of its onset in a terrestrian mammal, comprising measuring the expression level of a marker in a sample obtained from said terrestrian mammal and comparing said expression level to the expression level of said marker measured in a sample obtained from one or more terrestrian mammals of the same species not affected by osteochondrosis, wherein the marker is ApoB-3G, and wherein an increase in the expression level of ApoB-3G is indicative of osteochondrosis. The invention also provides a diagnostic kit for use in said method, which comprises at least one agent, which binds specifically to the product of the gene of the respective marker and which can be used to determine the expression level of said marker, wherein the marker is ApoB-3G.

Abstract: The present invention is related to accurate detection methods for the measurement only of myeloperoxidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.

Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.

Abstract: The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields.

Abstract: The present invention is related to accurate detection methods for the measurement only of myelopexidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.

Abstract: The present invention is related to a pharmaceutical composition suitable for the treatment and/or the prevention of atherosclerosis from infectious origin, which comprises an adequate pharmaceutical carrier, a corticosteroid and a stilbene-type alexin, preferably further comprising a flavonoid to regenerate the stilbene and/or to increase the effect of the latter. The latter compositions are highly suitable for long-term therapies like the treatment of atherosclerosis from infectious origin.